While the cost of ctDNA analysis is an important factor, the clinical benefits associated with early detection of ALK rearrangements and personalized treatment approaches suggest that ctDNA analysis could be a valuable tool in the management of ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.